LifeVantage (LFVN) 10-Q 5 Feb 25 2025 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Dec. 31, 2024	Feb. 04, 2025
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Dec. 31, 2024
Document Transition Report	false
Entity File Number	001-35647
Entity Registrant Name	LIFEVANTAGE CORP
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	90-0224471
Entity Address, Address Line One	3300 Triumph Blvd
Entity Address, Address Line Two	Suite 700
Entity Address, City or Town	Lehi
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84043
City Area Code	801
Local Phone Number	432-9000
Title of 12(b) Security	Common Stock, par value $0.0001
Trading Symbol	LFVN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		12,551,281
Amendment Flag	false
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q2
Entity Central Index Key	0000849146
Current Fiscal Year End Date	--06-30

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Dec. 31, 2024	Jun. 30, 2024
Current assets
Cash and cash equivalents	$ 21,595	$ 16,886
Accounts receivable	2,087	2,949
Income tax receivable	0	313
Inventory, net	17,467	15,055
Prepaid expenses and other	4,641	2,443
Total current assets	45,790	37,646
Long-term assets
Property and equipment, net	7,136	7,813
Right-of-use assets	8,915	9,569
Intangible assets, net	257	323
Deferred income tax asset	5,784	4,268
Other long-term assets	645	680
TOTAL ASSETS	68,527	60,299
Current liabilities
Accounts payable	5,757	5,853
Commissions payable	7,944	6,569
Income tax payable	660	202
Lease liabilities	1,886	1,811
Other accrued expenses	11,302	7,874
Total current liabilities	27,549	22,309
Long-term lease liabilities	10,883	11,801
Other long-term liabilities	206	198
Total liabilities	38,638	34,308
Commitments and contingencies - Note 7
Stockholders’ equity
Preferred stock — par value $0.0001 per share, 5,000 shares authorized, no shares issued or outstanding	0	0
Common stock — par value $0.0001 per share, 40,000 shares authorized and 12,550 and 12,510 issued and outstanding as of December 31, 2024 and June 30, 2024, respectively	1	1
Additional paid-in capital	138,171	136,644
Accumulated deficit	(106,478)	(108,738)
Accumulated other comprehensive loss	(1,805)	(1,916)
Total stockholders’ equity	29,889	25,991
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 68,527	$ 60,299

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Dec. 31, 2024	Jun. 30, 2024
Statement of Financial Position [Abstract]
Preferred stock, par value (in USD per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in USD per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	40,000,000	40,000,000
Common stock, shares issued (in shares)	12,550,000	12,510,000
Common stock, shares outstanding (in shares)	12,550,000	12,510,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Income Statement [Abstract]
Revenue, net	$ 67,762	$ 51,624	$ 114,976	$ 102,988
Cost of sales	13,195	11,066	22,686	21,246
Gross profit	54,567	40,558	92,290	81,742
Operating expenses:
Commissions and incentives	32,525	21,754	52,830	44,227
Selling, general and administrative	18,614	20,065	33,462	38,027
Total operating expenses	51,139	41,819	86,292	82,254
Operating income (loss)	3,428	(1,261)	5,998	(512)
Other income (expense):
Interest income, net	130	108	189	276
Other income (expense), net	(469)	41	(520)	(47)
Total other income (expense)	(339)	149	(331)	229
Income (loss) before income taxes	3,089	(1,112)	5,667	(283)
Income tax benefit (expense)	(539)	456	(1,291)	256
Net income (loss)	$ 2,550	$ (656)	$ 4,376	$ (27)
Net income (loss) per share:
Basic (in USD per share)	$ 0.21	$ (0.05)	$ 0.36	$ 0
Diluted (in USD per share)	$ 0.19	$ (0.05)	$ 0.34	$ 0
Weighted-average shares outstanding:
Basic (in shares)	12,211	12,612	12,166	12,574
Diluted (in shares)	13,177	12,612	12,903	12,574
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	$ (680)	$ 463	$ 111	$ 169
Other comprehensive income (loss), net of tax	(680)	463	111	169
Comprehensive income (loss)	$ 1,870	$ (193)	$ 4,487	$ 142

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)
Beginning balance (in shares) at Jun. 30, 2023		12,622
Beginning balance at Jun. 30, 2023	$ 34,649	$ 1	$ 134,314	$ (98,305)	$ (1,361)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	978		978
Common stock issued under equity award plans (in shares)		281
Shares canceled or surrendered as payment of tax withholding and other (in shares)		(90)
Shares canceled or surrendered as payment of tax withholding and other	(465)		(465)
Repurchase of company stock (in shares)		(145)
Repurchase of company stock	(795)			(795)
Common stock issued under employee stock purchase plan (in shares)		39
Common stock issued under employee stock purchase plan	126		126
Cash dividends	(5,534)			(5,534)
Currency translation adjustment	(294)				(294)
Net income	629			629
Ending balance (in shares) at Sep. 30, 2023		12,707
Ending balance at Sep. 30, 2023	29,294	$ 1	134,953	(104,005)	(1,655)
Beginning balance (in shares) at Jun. 30, 2023		12,622
Beginning balance at Jun. 30, 2023	$ 34,649	$ 1	134,314	(98,305)	(1,361)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Repurchase of company stock (in shares)	(400)
Common stock issued under employee stock purchase plan (in shares)	39
Net income	$ (27)
Ending balance (in shares) at Dec. 31, 2023		12,880
Ending balance at Dec. 31, 2023	27,307	$ 1	135,490	(106,992)	(1,192)
Beginning balance (in shares) at Sep. 30, 2023		12,707
Beginning balance at Sep. 30, 2023	29,294	$ 1	134,953	(104,005)	(1,655)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	750		750
Common stock issued under equity award plans (in shares)		495
Shares canceled or surrendered as payment of tax withholding and other (in shares)		(34)
Shares canceled or surrendered as payment of tax withholding and other	$ (213)		(213)
Repurchase of company stock (in shares)	(300)	(288)
Repurchase of company stock	$ (1,876)			(1,876)
Cash dividends	(455)			(455)
Currency translation adjustment	463				463
Net income	(656)			(656)
Ending balance (in shares) at Dec. 31, 2023		12,880
Ending balance at Dec. 31, 2023	$ 27,307	$ 1	135,490	(106,992)	(1,192)
Beginning balance (in shares) at Jun. 30, 2024	12,510	12,510
Beginning balance at Jun. 30, 2024	$ 25,991	$ 1	136,644	(108,738)	(1,916)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	917		917
Common stock issued under equity award plans (in shares)		140
Shares canceled or surrendered as payment of tax withholding and other (in shares)		(48)
Shares canceled or surrendered as payment of tax withholding and other	(347)		(347)
Repurchase of company stock (in shares)		(140)
Repurchase of company stock	(1,114)			(1,114)
Common stock issued under employee stock purchase plan (in shares)		22
Common stock issued under employee stock purchase plan	133		133
Cash dividends	(500)			(500)
Currency translation adjustment	791				791
Net income	1,826			1,826
Ending balance (in shares) at Sep. 30, 2024		12,484
Ending balance at Sep. 30, 2024	$ 27,697	$ 1	137,347	(108,526)	(1,125)
Beginning balance (in shares) at Jun. 30, 2024	12,510	12,510
Beginning balance at Jun. 30, 2024	$ 25,991	$ 1	136,644	(108,738)	(1,916)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Repurchase of company stock (in shares)	(100)
Common stock issued under employee stock purchase plan (in shares)	22
Net income	$ 4,376
Ending balance (in shares) at Dec. 31, 2024	12,550	12,550
Ending balance at Dec. 31, 2024	$ 29,889	$ 1	138,171	(106,478)	(1,805)
Beginning balance (in shares) at Sep. 30, 2024		12,484
Beginning balance at Sep. 30, 2024	27,697	$ 1	137,347	(108,526)	(1,125)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	1,722		1,722
Common stock issued under equity award plans (in shares)		133
Shares canceled or surrendered as payment of tax withholding and other (in shares)		(67)
Shares canceled or surrendered as payment of tax withholding and other	$ (898)		(898)
Repurchase of company stock (in shares)	0
Cash dividends	$ (502)			(502)
Currency translation adjustment	(680)				(680)
Net income	$ 2,550			2,550
Ending balance (in shares) at Dec. 31, 2024	12,550	12,550
Ending balance at Dec. 31, 2024	$ 29,889	$ 1	$ 138,171	$ (106,478)	$ (1,805)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Cash Flows from Operating Activities:
Net income (loss)	$ 4,376	$ (27)
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	1,603	1,880
Stock-based compensation	2,639	1,728
Non-cash operating lease expense	709	575
Gain on disposal of assets	(4)	0
Amortization of debt discount	16	0
Deferred income tax	(1,516)	(1,627)
Changes in operating assets and liabilities:
Accounts receivable	872	(703)
Income tax receivable	313	7
Inventory, net	(2,473)	1,183
Prepaid expenses and other	(2,207)	970
Other long-term assets	33	61
Accounts payable	(91)	2,641
Income tax payable	458	825
Other accrued expenses	4,787	(491)
Lease liabilities	(899)	(674)
Other long-term liabilities	0	174
Net Cash Provided by Operating Activities	8,616	6,522
Cash Flows from Investing Activities:
Proceeds from sale of property and equipment	4	0
Purchase of property and equipment	(841)	(1,676)
Net Cash Used in Investing Activities	(837)	(1,676)
Cash Flows from Financing Activities:
Repurchase of company stock	(1,114)	(2,671)
Payment of cash dividends	(1,002)	(5,989)
Shares canceled or surrendered as payment of tax withholding and other	(1,245)	(678)
Proceeds from common stock issued under employee stock purchase plan	133	126
Net Cash Used in Financing Activities	(3,228)	(9,212)
Foreign Currency Effect on Cash	158	92
Increase (decrease) in Cash and Cash Equivalents:	4,709	(4,274)
Cash and Cash Equivalents — beginning of period	16,886	21,605
Cash and Cash Equivalents — end of period	21,595	17,331
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest	1	3
Cash paid for income taxes	$ 2,063	$ 633

Organization and Basis of Prese

Organization and Basis of Presentation	6 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation LifeVantage is a company focused on nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. The Company is dedicated to helping people achieve their health, wellness and financial goals. The Company provides quality, scientifically-validated products to customers and independent consultants as well as a financially rewarding commission-based direct sales opportunity to its independent consultants. LifeVantage sells its products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The Company engages in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, weight management products, skin and hair care products, nootropics, and pre- and pro-biotics. The Company's line of scientifically validated dietary supplements includes its flagship Protandim® family of products, the MindBody GLP-1 System ™ , LifeVantage ® Omega+, ProBio, IC Bright ® , the Rise AM & Reset PM System ® , D3+, Daily Wellness, PhysIQ Fat Burn and Prebiotic dietary supplements. TrueScience ® is the Company's line of skin and hair care products and Liquid Collagen. The Company also markets and sells Petandim ® , its companion pet supplement formulated to combat oxidative stress in dogs; and AXIO ® , its nootropic energy drink mixes. The condensed consolidated financial statements included herein have been prepared by the Company’s management, without audit, pursuant to the rules and regulations of the SEC. In the opinion of the Company’s management, these interim financial statements include all adjustments that are considered necessary for a fair presentation of its financial position as of December 31, 2024, and the results of operations for the three and six months ended December 31, 2024 and 2023, and the cash flows for the six months ended December 31, 2024 and 2023. Interim results are not necessarily indicative of results for a full year or for any future period. The condensed consolidated financial statements and notes included herein are presented as required by Form 10-Q, and do not contain certain information included in the Company’s audited financial statements and notes for the fiscal year ended June 30, 2024, pursuant to the rules and regulations of the SEC. For further information, refer to the financial statements and notes thereto as of and for the year ended June 30, 2024, and included in the annual report on Form 10-K on file with the SEC.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation. Use of Estimates The Company prepares the condensed consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America ("GAAP"). In preparing these statements, the Company is required to use estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates and assumptions. On an ongoing basis, the Company reviews its estimates, including, but not limited to, those related to inventory valuation and obsolescence, sales returns, income taxes and tax valuation reserves, transfer pricing methodology and positions, impairment of assets, share-based compensation, and loss contingencies. Foreign Currency Translation A portion of the Company’s business operations occurs outside the United States. The local currency of each of the Company’s subsidiaries is generally its functional currency. All assets and liabilities are translated into U.S. dollars at exchange rates existing at the balance sheet dates, revenue and expenses are translated at weighted-average exchange rates and stockholders’ equity is recorded at historical exchange rates. The resulting foreign currency translation adjustments are recorded as a separate component of stockholders’ equity in the condensed consolidated balance sheets and as a component of com prehensive income. Transaction gains and losses are included in other expense, net in the condensed consolidated statements of operations and comprehensive income. For the three months ended December 31, 2024 and 2023, net foreign currency losses of approximately $0.5 million and net foreign currency gains of approximately $37,000, respectively, are recorded in other expense, net. For the six months ended December 31, 2024 and 2023, net foreign currency losses of approximately $0.5 million and $0.1 million, respectively, are recorded in other expense, net. Cash and Cash Equivalents The Company considers only its monetary liquid assets with original maturities of three months or less as cash and cash equivalents. Concentration of Credit Risk Accounting guidance for financial instruments requires disclosure of significant concentrations of credit risk regardless of the degree of such risk. Financial instruments with significant credit risk include cash and investments. At December 31, 2024, the Company had $18.0 million in cash accounts at one financial institution and $3.6 million in accounts at other financial institutions. At June 30, 2024, the Company had $12.6 million in cash accounts at one financial institution and $4.3 million in accounts at other financial institutions. As of December 31, 2024 and June 30, 2024, and during the periods then ended, the Company’s cash balances exceeded federally insured limits. Accounts Receivable The Company’s accounts receivable as of December 31, 2024 and June 30, 2024 consist primarily of credit card receivables. Based on the Company’s verification process for customer credit cards and historical information available, management has determined that an allowance for doubtful accounts on credit card sales related to its customer sales as of December 31, 2024 and June 30, 2024 is not necessary. No bad debt expense was recorded during the three and six months ended December 31, 2024 and 2023. Inventory As of December 31, 2024 and June 30, 2024, inventory consisted of (in thousands): December 31, June 30, Finished goods $ 13,900 79.6 % $ 11,841 78.7 % Raw materials 3,567 20.4 % 3,214 21.3 % Total inventory $ 17,467 100.0 % $ 15,055 100.0 % Inventories are carried at the lower of cost or net realizable value, using the first-in, first-out method, which includes a reduction in inventory values of $1.0 million and $1.3 million at December 31, 2024 and June 30, 2024, respectively, related to obsolete and slow-moving inventory. Fair Value of Financial Instruments The Company accounts for assets and liabilities using a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company's market assumptions. These two types of inputs have created the fair-value hierarchy below. This hierarchy requires the Company to minimize the use of unobservable inputs and to use observable market data, if available, when determining fair value. • Level 1—Quoted prices for identical instruments in active markets; • Level 2—Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and • Level 3—Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Our financial instruments, consisting primarily of cash and cash equivalents, accounts receivable, and accounts payable, approximate fair value due to their short-term nature. Revenue Recognition Revenue is recognized when control of the promised goods or services is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales, value-added, and other taxes the Company collects concurrent with revenue-producing activities are excluded from revenue. The Company generates the majority of its revenue through product sales to customers. These products include the Protandim ® line of dietary supplements, the MindBody GLP-1 System ™ , LifeVantage ® Omega+, ProBio, IC Bright ® , the Rise AM & Reset PM System ® , D3+, Daily Wellness, PhysIQ Fat Burn and Prebiotic dietary supplements, TrueScience ® skin and hair care products and Liquid Collagen, Petandim ® , and AXIO ® nootropic energy drink mixes. The Company ships most of its product directly to the consumer and receives substantially all payment for product sales in the form of credit card receipts. Revenue from direct product sales to customers is recognized upon shipment, which is when passage of title and risk of loss occurs. For items sold in packs and bundles, the Company determines the standalone selling price at contract inception for each distinct good and then allocates the transaction price on a relative standalone selling price basis. Any discounts are accounted for as a direct reduction to the transaction price. Shipping and handling revenue is recognized upon shipment when the performance obligation is completed. Contract liabilities, recorded as deferred revenue, include loyalty program credit deferrals with certain customers which are accounted for as a reduction in the transaction price and are generally recognized as credits which are redeemed for additional products at a later date. The Company also records deferred revenue when cash payments are received or due in advance of performance, including amounts which are refundable. In addition, the Company pre-sells tickets to its events. When cash p ayments are received in advance of events, the cash received is recorded to deferred revenue until the event is held, at which time the Company has performed its obligations under the contract and the revenue is recognized. Deferred revenue is included in accrued expenses in the consolidated balance sheets. The balance of deferred revenue related to contract liabilities was $1.4 million and $0.9 million as of December 31, 2024 and June 30, 2024, respectively. The contract liabilities impact to revenue for the three months ended December 31, 2024 and 2023 was a decrease of $0.3 million and an increase of $0.1 million, respectively. The contract liabilities impact to revenue for the six months ended December 31, 2024 and 2023 was a decrease of $0.5 million and $40,000, respectively. Estimated returns are recorded when a product is shipped. Subject to some exceptions based on local regulations, the Company’s return policy is to provide a full refund for a product returned within 30 days. After 30 days of purchase, only unopened product that is in a resalable and restockable condition may be returned within twelve months of purchase and shall receive a 100% refund, less a 10% handling and restocking fee and any shipping and handling costs. The Company establishes a refund liability reserve, and an asset reserve for its right to recover products, based on historical experience. The returns asset reserve and returns liability reserve are evaluated on a quarterly basis. As of December 31, 2024 and June 30, 2024, the returns liability reserve, net was $0.2 million and $0.1 million, respectively. Shipping and Handling Shipping and handling costs associated with inbound freight and freight out to customers and independent consultants are included in cost of sales. Shipping and handling fees charged to customers and independent consultants are included in revenue. Research and Development Costs The Company expenses all costs related to research and development activities, as incurred. Research and development expens es for the three months ended December 31, 2024 and 2023 were $0.2 million and $0.1 million, respectively. Research and development expens es for the six months ended December 31, 2024 and 2023 were $0.5 million and $0.3 million, respectively. Leases The Company accounts for leases in accordance with Accounting Standards Codification ("ASC") 842. The Company reviews all contracts and determines if the arrangement is or contains a lease, at inception. Operating leases are included in right-of-use (“ROU”) assets, current lease liabilities and long-term lease liabilities on the condensed consolidated balance sheets. The Company does not have any finance leases. Operating lease ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company uses its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any upfront lease payments made and excludes lease incentives and initial direct costs incurred. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with a term of 12 months or less are not recorded on the balance sheet. The Company’s lease agreements do not contain any residual value guarantees. Stock-Based Compensation The Company recognizes stock-based compensation by measuring the cost of services to be rendered based on the grant date fair value of the equity award. The Company recognizes stock-based compensation, net of any estimated forfeitures, over the period an employee is required to provide service in exchange for the award, generally referred to as the requisite service period. The Company estimates forfeitures based on historical information and other management assumptions. The Black-Scholes option pricing model is used to estimate the fair value of stock options and options under the Company's 2019 Employee Stock Purchase Plan (as amended, the "2019 ESPP"). The determination of the fair value of options is affected by the Company's stock price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The Company uses historical data for estimating the expected volatility and expected life of stock options required in the Black-Scholes model. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected terms of the stock options. The fair value of restricted stock grants, including performance restricted stock units that include non-market based performance conditions, is based on the closing market price of the Company's stock on the date of grant less the Company's expected dividend yield. The Company recognizes compensation costs for awards with performance conditions when it concludes it is probable that the performance conditions will be achieved. The Company reassesses the probability of vesting at each balance sheet date and adjusts compensation costs accordingly. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled, updated as needed for changes in corporate tax rates. The effect on deferred tax assets and liabilities from a change in tax rates is recognized in income in the period that includes the effective date of the change. The Company recognizes tax liabilities or benefits from an uncertain position only if it is more likely than not that the position will be sust ained upon examination by taxing authorities based on the technical merits of the issue. The amount recognized would be the largest liability or benefit that the Company believes has greater than a 50% likelihood of being realized upon settlement. For the three months ended December 31, 2024 and 2023, the Company recognized income tax expense of $0.5 million and a benefit of $0.5 million, respectively. For the six months ended December 31, 2024 and 2023, the Company recognized income tax expense of $1.3 million and a benefit of $0.3 million, respectively. Tax expenses are reflective of the Company’s current estimated federal, state and foreign effective tax rate. Realization of deferred tax assets is dependent upon future earnings in specific tax jurisdictions, the timing and amount of which are uncertain. Income Per Share Basic income per common share is computed by dividing the net income by the weighted-average number of common shares outstanding during the period, less unvested restricted stock awards. Diluted income per common share is computed by dividing net income by the weighted-average common shares and potentially dilutive common share equivalents using the treasury stock method. For the three months ended December 31, 2024 and 2023, the effects of approximately 0.1 million and 26,000 common shares, respectively, issuable upon exercise of options and non-vested shares of restricted stock are not included in computations as their effect was anti-dilutive. For the six months ended December 31, 2024 and 2023, the effects of approximately 0.1 million and 0.1 million common shares, respectively, issuable upon exercise of options and non-vested shares of restricted stock are not included in computations as their effect was anti-dilutive. The following is a reconciliation of net income per share and the weighted-average common shares outstanding for purposes of computing basic and diluted net income per share (in thousands, except per share amounts): Three Months Ended December 31, Six Months Ended December 31, 2024 2023 2024 2023 Numerator: Net income (loss) $ 2,550 $ (656) $ 4,376 $ (27) Denominator: Basic weighted-average common shares outstanding 12,211 12,612 12,166 12,574 Effect of dilutive securities: Stock awards and options 966 — 737 — Diluted weighted-average common shares outstanding 13,177 12,612 12,903 12,574 Net income (loss) per share, basic $ 0.21 $ (0.05) $ 0.36 $ 0.00 Net income (loss) per share, diluted $ 0.19 $ (0.05) $ 0.34 $ 0.00 Segment Information and Disaggregated Revenue The Company operates in a single operating segment by selling products directly to customers and through an international network of independent consultants that operates in an integrated manner from market to market. Commissions and incentives expenses are the Company’s largest expense comprised of the commissions paid to its independent consultants. The Company manages its business primarily by managing its international network of independent consultants. The Company disaggregates revenue in two geographic regions: the Americas region and the Asia/Pacific & Europe region. The following table presents the Company's revenue disaggregated by these two geographic regions (in thousands): Three Months Ended December 31, Six Months Ended December 31, 2024 2023 2024 2023 Americas $ 57,154 $ 39,065 $ 94,046 $ 77,580 Asia/Pacific & Europe 10,608 12,559 20,930 25,408 Total revenue $ 67,762 $ 51,624 $ 114,976 $ 102,988 Additional information as to the Company’s revenue from operations in the most significant geographical areas is set forth below (in thousands): Three Months Ended December 31, Six Months Ended December 31, 2024 2023 2024 2023 United States $ 55,381 $ 37,219 $ 90,649 $ 74,115 Japan $ 6,278 $ 7,314 $ 12,261 $ 14,828 The following table presents the Company's long-lived assets for its most significant geographic markets (in thousands): December 31, June 30, United States $ 19,582 $ 19,216 Japan $ 1,879 $ 1,925 New Accounting Pronouncements In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"), expanding segment disclosure requirements. The amendments require enhanced disclosure for certain segment items and required disclosure on how management uses reported measures to assess segment performance. The amendments do not change how segments are determined, aggregated, or how thresholds are applied to determine reportable segments. ASU 2023-07 is effective for the Company’s annual periods beginning July 1, 2024, and for interim periods beginning July 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"). The guidance requires disclosure of disaggregated income taxes paid, prescribes standardized categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU 2023-09 is effective for the Company’s annual periods beginning July 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures. In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses ("ASU 2024-03"). The guidance requires disclosure, in the notes to financial statements, of specific information about certain costs and expenses at each interim and annual reporting period. ASU 2024-03 is effective for the Company’s annual periods beginning July 1, 2027, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures. Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company's present or future financial statements.

Leases

Leases	6 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Leases	Leases The Company has operating leases for current corporate offices and certain equipment. These leases have remaining terms of appro ximately one As of December 31, 2024, the weighted average remaining lease term and weighted average discount rate for operating leases was 6.43 years and 3.45%, respectively. As of June 30, 2024, the weighted average remaining lease term and weighted average discount rate for operating leases was 6.90 years and 3.46%, respectively. For the three months ended December 31, 2024 and 2023, operating lease expense was $0.5 million and $0.5 million, respectively. For the six months ended December 31, 2024 and 2023, operating lease expense was $1.0 million and $1.1 million, respectively. The components of lease expense for the three and six months ended December 31, 2024 and 2023, were as follows: Three Months Ended December 31, Six Months Ended December 31, 2024 2023 2024 2023 Operating lease expense Operating lease cost $ 468 $ 462 $ 938 $ 992 Variable lease cost 33 45 74 94 Short-term lease costs 4 12 9 23 Total lease expense $ 505 $ 519 $ 1,021 $ 1,109 Supplemental cash flow information related to operating leases was as follows (in thousands): Three Months Ended December 31, Six Months Ended December 31, 2024 2023 2024 2023 Operating cash outflows from operating leases $ 564 $ 755 $ 1,129 $ 1,090 Right-of-use assets obtained in exchange for lease obligations $ — $ — $ — $ 1,502 Maturity of lease liabilities at December 31, 2024 are as follows (in thousands): Year ended June 30, Amount 2025 (remaining six months ending June 30, 2025) $ 1,142 2026 2,314 2027 2,316 2028 2,045 2029 1,772 Thereafter 4,622 Total 14,211 Less: imputed interest (1,442) Present value of lease liabilities $ 12,769

Long-Term Debt

Long-Term Debt	6 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt On April 12, 2024, the Company entered into a Loan Agreement (the “Loan Agreement”) with Bank of America, N.A., as Lender (the “Lender”). In connection with the Loan Agreement and on the same date, the Company, Lifeline Nutraceuticals Corporation, as Guarantor (the “Guarantor”), and the Lender also entered into a Continuing and Unconditional Guaranty (the “Continuing and Unconditional Guaranty”) and a Security and Pledge Agreement (the “Security and Pledge Agreement”). The Loan Agreement provides for a revolving line of credit in an aggregate principal amount not to exceed $5.0 million (the “Line of Credit” and collectively with the Loan Agreement, Continuing and Unconditional Guaranty and the Security and Pledge Agreement the “2024 Credit Facility”). In the event the Company borrows under the Line of Credit, interest will be payable commencing on the last day of each month following such borrowing until payment in full of all principal outstanding under the Line of Credit, with all unpaid principal and interest due on April 12, 2027 (the “Expiration Date”). The Line of Credit will bear interest at a rate per year equal to the sum of (i) the greater of the Term Secured Overnight Financing Rate Daily Floating Rate (as defined in the Loan Agreement) or 0.00% , plus (ii) 2.00%. Amounts under the Line of Credit may be repaid and re-borrowed from time to time until the Expiration Date. As of December 31, 2024, the effective interest rate is 6.49%. The Company’s obligations under the Loan Agreement are secured by a security interest in substantially all of the assets of the Company and the Guarantor, and by a pledge of the membership interests of the Company's subsidiaries, as further provided for in the Security and Pledge Agreement. Pursuant to the Continuing and Unconditional Guaranty, the Guarantor guarantees and promises to pay promptly to the Lender all indebtedness of the Company when due. The Loan Agreement contains customary covenants, both affirmative and negative, that, among other things, restrict the Company’s ability to deal with the Company's assets outside of the ordinary course, incur additional indebtedness, grant liens on the Company's assets, make certain investments, purchase or otherwise acquire all or substantially all the assets or equity interests of other companies, and enter into consolidations, mergers or other combinations. The Loan Agreement requires that the Company maintain specified financial ratios and satisfy certain financial condition tests. The Loan Agreement contains certain customary events of default, including, among other things, failure of the Company to make required payments under the Loan Agreement, certain breaches of representations made by the Company or the Guarantor, insolvency or bankruptcy of the Company or the Guarantor, failure to have an enforceable first lien or security interest in any property given as security for the Loan Agreement, or failure of the Company to comply with covenants set forth in the Loan Agreement. If an event of default occurs under the Loan Agreement, the obligation of the Lender to make any additional credit available to the Company may be terminated and the amounts outstanding may become immediately due and payable in the discretion of the Lender, provided that in the event of insolvency or bankruptcy of the Company or the Guarantor, all debts outstanding under the Loan Agreement will automatically become due and payable. Upon the occurrence of any default or after maturity, all amounts outstanding under the Loan Agreement will, at the option of the Lender, bear interest at a rate which is 2.00% higher than the rate of interest otherwise provided under the Loan Agreement.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Dec. 31, 2024
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity During the three months ended December 31, 2024 and 2023 , the Company issued 0.1 million and 0.5 million shares of common stock, respectively, under Company stock plans. During the three months ended December 31, 2024 and 2023 , the Company issued zero shares of common stock upon the exercise of stock options. During the three months ended December 31, 2024 and 2023, 0.1 million and 34,000 shares of restricted stock, respectively, were canceled or surrendered as payment of tax withholding upon vesting of equity awards. During the six months ended December 31, 2024 and 2023 , the Company issued 0.3 million and 0.8 million shares of common stock, respectively, under Company stock plans. During the six months ended December 31, 2024 and 2023 , the Company issued zero shares of common stock upon the exercise of stock options. During the six months ended December 31, 2024 and 2023, 0.1 million and 0.1 million shares of restricted stock, respectively, were canceled or surrendered as payment of tax withholding upon vesting of equity awards. O n February 17, 2022, the Company's board of directors (the "Board of Directors") approved an amendment to its then-existing share repurchase program to increase the authorized share repurchase amount from $35.0 million to $60.0 million. On June 12, 2023, the Board of Directors approved an amendment to extend the duration of the repurchase program period to December 31, 2026. During the three and six months ended December 31, 2024, the Company purchased zero shares and 0.1 million shares of common stock at an aggregate price of zero and $1.1 million, respectively, under this repurchase program. During the three and six months ended December 31, 2023 , the Company purchased 0.3 million shares and 0.4 million shares of common stock at an aggregate price of $1.9 million and $2.7 million, respectively, under this repurchase program. At December 31, 2024, there was $19.3 million remaining under this repurchase program. On August 30, 2023, the Board of Directors approved a stockholder rights agreement (the “Rights Plan”) and declared a dividend of one right for each outstanding share of common stock to stockholders of record on September 11, 2023. Each right entitled holders to purchase one newly issued share of preferred stock at an exercise price of $20 per right, subject to adjustment. Initially, the rights were not exercisable and traded with shares of the Company’s common stock. In general, the rights would have become exercisable following a public announcement that a person acquires 12% (or, in the case of passive investors, 20%) or more of the outstanding shares of the Company’s common stock. If a person became an acquiring person, each holder of rights (except the acquiring person) would have had the right to purchase, for the purchase price, a number of shares of the Company’s common stock at a 50% discount to the then-current trading price. Rather than allowing the rights to be exercised in those circumstances, the Board of Directors could exchange each right, other than the rights owned by the acquiring person, for a share of the Company’s common stock. The agreement provided for exceptions and additional terms for other certain situations and circumstances. The Rights Plan was intended to protect the interests of LifeVantage and its stockholders by reducing the likelihood that any entity, person or group gains control of the Company through open-market accumulation or other means without payment of an adequate control premium and expired on August 28, 2024. There was no impact to the Company’s Consolidated Financial Statements. The Company’s Certificate of Incorporation authorizes the issuance of preferred stock. However , as of December 31, 2024, none have been issued nor have any rights or preferences been assigned to the preferred stock by the Board of Directors. Dividends In August 2024, the Board of Directors declared a quarterly cash dividend of $0.04 per share of common stock to be paid on September 17, 2024 to stockholders of record on September 9, 2024. In October 2024, the Board of Directors declared a quarterly cash dividend of $0.04 per share of common stock to be paid on December 16, 2024 to stockholders of record on December 2, 2024. Cash dividends for the three and six months ended December 31, 2024 totaled $0.5 million and $1.0 million, respectively. Cash dividends for the three and six months ended December 31, 2023 totaled $0.5 million and $6.0 million, or $0.035 and $0.47 per share, respectively. The declaration of dividends is subject to the discretion of the Board of Directors and will depend upon various factors, including the Company's earnings, financial condition, restrictions imposed by any indebtedness that may be outstanding, cash requirements, future prospects and other factors deemed relevant by the Board of Directors.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation Long-Term Incentive Plans Equity-Settled Plans The Company's Board of Directors adopted, and the Company's stockholders approved, the 2017 Long-Term Incentive Plan (as amended, the “2017 Plan”), effective February 16, 2017, to provide incentives to eligible employees, directors and consultants. The initial shares reserved under the 2017 Plan was (i) 650,000 shares plus (ii) 475,000 shares previously reserved for issuance under the Company’s 2010 Long Term Incentive Plan (the “2010 Plan”), including upon cancellation, termination or forfeiture of awards previously granted under the 2010 Plan, plus (iii) shares subject to forfeited or terminated awards, or shares that are withheld or surrendered from an award to pay an award’s exercise price or tax withholding obligations, in each case where such awards have been granted under the 2017 Plan. In February 2018, November 2018, November 2020, November 2022 and November 2023, the Company’s stockholders approved amendments to the 2017 Plan to increase the number of shares of the Company’s common stock that are available for issuance under the 2017 Plan by 425,000 , 715,000 , 650,000 , 1,052,000, and 1,138,000 shares, respectively. Further, in November 2024, the Company’s stockholders approved an amendment to remove individual grant limitations under the 2017 Plan and certain performance-based provisions, both of which are no longer applicable following the repeal of the performance-based exemption in Section 162(m) of the Internal Revenue Code, as amended. As of December 31, 2024, an aggregate of 5.1 million shares of the Company's common stock were authorized to be issued under the 2017 Plan in connection with the grant of awards which is calculated as the sum of (i) 4,630,000 shares and (ii) up to 475,000 shares previously reserved for issuance under the 2010 Plan, including shares returned upon cancellation, termination or forfeiture of awards that were previously granted under that plan. As of December 31, 2024, there were stock option awards outstanding under the 2017 Plan, net of awards expired, for an aggregate of 0.1 million shares of the Company's common stock. Outstanding stock options awarded under the 2017 Plan have exercise prices of $4.44 per share, and vest over a three-year vesting period. Awards expire in accordance with the terms of each award and, upon expiration of the award, the shares subject to the award are added back to the 2017 Plan. The contractual term of stock options granted is generally ten years. Employee Stock Purchase Plan General. The Company's 2019 ESPP was adopted by the Company's Board of Directors in September 2018 and the Company's stockholders approved it in November 2018. In August 2024, the Board of Directors approved an amendment to the 2019 ESPP to increase the share reserve thereunder by 0.4 million shares, which amendment and increase was approved by the Company’s stockholders in November 2024. The 2019 ESPP is intended to qualify under Section 423 of the Internal Revenue Code. Share Reserve. The Company has reserved a total of 0.8 million shares of its common stock for issuance under the 2019 ESPP. As of December 31, 2024, 0.4 million shares were available for issuance. The number of shares reserved under the 2019 ESPP will automatically be adjusted in the event of a stock split, stock dividend or a reverse stock split (including an adjustment to the per-purchase period share limit). Purchase Price. Employees may purchase each share of common stock under the 2019 ESPP at a price equal to 85% of the lower of the fair market values of the stock as of the beginning or the end of the six-month offering periods. An employee's contributions to the 2019 ESPP are limited to 15% of their regular hourly or salary compensation, and up to a maximum of 3,000 shares may be purchased during any offering period. A participant shall not be granted an option under the 2019 ESPP if such option would permit the participant's rights to purchase stock to accrue at a rate exceeding $25,000 grant date fair market value of stock for each calendar year in which such option is outstanding at any time. Offering Periods. Unless otherwise determined by the compensation committee, the 2019 ESPP will be operated through a series of successive six-month offering periods, which will begin each year on March 1 and September 1. Duri ng the six months ended December 31, 2024 and 2023 , approximately 22,000 and 39,000 shares of common stock were issued under the 2019 ESPP, respectively. Stock-Based Compensation For the three months ended December 31, 2024 and 2023, compensation of $1.7 million and $0.8 million, respectively, was reflected as an increase to additional paid-in capital, all of which was employee related. For the six months ended December 31, 2024 and 2023, compensation of $2.6 million and $1.7 million, respectively, was reflected as an increase to additional

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Contingencies The Company accounts for contingent liabilities in accordance with ASC 450, Contingencies. This guidance requires management to assess potential contingent liabilities that may exist as of the date of the financial statements to determine the probability and amount of loss that may have occurred, which inherently involves an exercise of judgment. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. For loss contingencies considered remote, no accrual or disclosures are generally made. Management has assessed potential contingent liabilities as of December 31, 2024, and based on the assessment, there are no probable loss contingencies requiring accrual or disclosures within its financial statements. Legal Accruals In addition to commitments and obligations in the ordinary course of business, from time to time, the Company is subject to various claims, pending and potential legal actions, investigations relating to governmental laws and regulations and other matters arising out of the normal conduct of its business. Management assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in the consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because evaluating legal claims and litigation results are inherently unpredictable and unfavorable results could occur, assessing contingencies is highly subjective and requires judgments about future events. When evaluating contingencies, management may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed or asserted against the Company may be unsupported, exaggerated or unrelated to possible outcomes, and as such are not meaningful indicators of a potential liability. Management regularly reviews contingencies to determine the adequacy of financial statement accruals and related disclosures. The amount of ultimate loss may differ from these estimates. It is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable publicity or resolution of one or more of these contingencies. Whether any losses finally determined in any claim, action, investigation or proceeding or publicity related to such could reasonably have a material effect on the Company's business, financial condition, results of operations or cash flows will depend on a number of variables, including: the timing and amount of such losses; the structure and type of any remedies; the significance of the impact of any such losses, damages or remedies may have on the consolidated financial statements; and the unique facts and circumstances of the particular matter that may give rise to additional factors. Other Matters.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2024	Dec. 31, 2023
Pay vs Performance Disclosure
Net income (loss)	$ 2,550	$ 1,826	$ (656)	$ 629	$ 4,376	$ (27)

Insider Trading Arrangements

Insider Trading Arrangements	6 Months Ended
	Dec. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Consolidation	Consolidation
Use of Estimates	Use of Estimates The Company prepares the condensed consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America ("GAAP"). In preparing these statements, the Company is required to use estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates and assumptions. On an ongoing basis, the Company reviews its estimates, including, but not limited to, those related to inventory valuation and obsolescence, sales returns, income taxes and tax valuation reserves, transfer pricing methodology and positions, impairment of assets, share-based compensation, and loss contingencies.
Foreign Currency Translation	Foreign Currency Translation A portion of the Company’s business operations occurs outside the United States. The local currency of each of the Company’s subsidiaries is generally its functional currency. All assets and liabilities are translated into U.S. dollars at exchange rates existing at the balance sheet dates, revenue and expenses are translated at weighted-average exchange rates and stockholders’ equity is recorded at historical exchange rates. The resulting foreign currency translation adjustments are recorded as a separate component of stockholders’ equity in the condensed consolidated balance sheets and as a component of com
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers only its monetary liquid assets with original maturities of three months or less as cash and cash equivalents.
Concentration of Credit Risk	Concentration of Credit Risk Accounting guidance for financial instruments requires disclosure of significant concentrations of credit risk regardless of the degree of
Accounts Receivable	Accounts Receivable
Inventory	Inventories are carried at the lower of cost or net realizable value, using the first-in, first-out method
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company accounts for assets and liabilities using a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company's market assumptions. These two types of inputs have created the fair-value hierarchy below. This hierarchy requires the Company to minimize the use of unobservable inputs and to use observable market data, if available, when determining fair value. • Level 1—Quoted prices for identical instruments in active markets; • Level 2—Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and • Level 3—Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
Revenue Recognition & Shipping and Handling	Revenue Recognition Revenue is recognized when control of the promised goods or services is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales, value-added, and other taxes the Company collects concurrent with revenue-producing activities are excluded from revenue. The Company generates the majority of its revenue through product sales to customers. These products include the Protandim ® line of dietary supplements, the MindBody GLP-1 System ™ , LifeVantage ® Omega+, ProBio, IC Bright ® , the Rise AM & Reset PM System ® , D3+, Daily Wellness, PhysIQ Fat Burn and Prebiotic dietary supplements, TrueScience ® skin and hair care products and Liquid Collagen, Petandim ® , and AXIO ® nootropic energy drink mixes. The Company ships most of its product directly to the consumer and receives substantially all payment for product sales in the form of credit card receipts. Revenue from direct product sales to customers is recognized upon shipment, which is when passage of title and risk of loss occurs. For items sold in packs and bundles, the Company determines the standalone selling price at contract inception for each distinct good and then allocates the transaction price on a relative standalone selling price basis. Any discounts are accounted for as a direct reduction to the transaction price. Shipping and handling revenue is recognized upon shipment when the performance obligation is completed. Contract liabilities, recorded as deferred revenue, include loyalty program credit deferrals with certain customers which are accounted for as a reduction in the transaction price and are generally recognized as credits which are redeemed for additional products at a later date. The Company also records deferred revenue when cash payments are received or due in advance of performance, including amounts which are refundable. In addition, the Company pre-sells tickets to its events. When cash p ayments are received in advance of events, the cash received is recorded to deferred revenue until the event is held, at which time the Company has performed its obligations under the contract and the revenue is recognized. Deferred revenue is included in accrued expenses in the consolidated balance sheets. The balance of deferred revenue related to contract liabilities was $1.4 million and $0.9 million as of December 31, 2024 and June 30, 2024, respectively. The contract liabilities impact to revenue for the three months ended December 31, 2024 and 2023 was a decrease of $0.3 million and an increase of $0.1 million, respectively. The contract liabilities impact to revenue for the six months ended December 31, 2024 and 2023 was a decrease of $0.5 million and $40,000, respectively. Estimated returns are recorded when a product is shipped. Subject to some exceptions based on local regulations, the Company’s return policy is to provide a full refund for a product returned within 30 days. After 30 days of purchase, only unopened product that is in a resalable and restockable condition may be returned within twelve months of purchase and shall receive a 100% refund, less a 10% handling and restocking fee and any shipping and handling costs. The Company establishes a refund liability reserve, and an asset reserve for its right to recover products, based on historical experience. The returns asset reserve and returns liability reserve are evaluated on a quarterly basis. As of December 31, 2024 and June 30, 2024, the returns liability reserve, net was $0.2 million and $0.1 million, respectively. Shipping and Handling Shipping and handling costs associated with inbound freight and freight out to customers and independent consultants are included in cost of sales. Shipping and handling fees charged to customers and independent consultants are included in revenue.
Research and Development Costs	Research and Development Costs
Leases	Leases The Company accounts for leases in accordance with Accounting Standards Codification ("ASC") 842. The Company reviews all contracts and determines if the arrangement is or contains a lease, at inception. Operating leases are included in right-of-use (“ROU”) assets, current lease liabilities and long-term lease liabilities on the condensed consolidated balance sheets. The Company does not have any finance leases. Operating lease ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company uses its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any upfront lease payments made and excludes lease incentives and initial direct costs incurred. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with a term of 12 months or less are not recorded on the balance sheet. The Company’s lease agreements do not contain any residual value guarantees.
Stock-Based Compensation	Stock-Based Compensation The Company recognizes stock-based compensation by measuring the cost of services to be rendered based on the grant date fair value of the equity award. The Company recognizes stock-based compensation, net of any estimated forfeitures, over the period an employee is required to provide service in exchange for the award, generally referred to as the requisite service period. The Company estimates forfeitures based on historical information and other management assumptions. The Black-Scholes option pricing model is used to estimate the fair value of stock options and options under the Company's 2019 Employee Stock Purchase Plan (as amended, the "2019 ESPP"). The determination of the fair value of options is affected by the Company's stock price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The Company uses historical data for estimating the expected volatility and expected life of stock options required in the Black-Scholes model. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected terms of the stock options. The fair value of restricted stock grants, including performance restricted stock units that include non-market based performance conditions, is based on the closing market price of the Company's stock on the date of grant less the Company's expected dividend yield. The Company recognizes compensation costs for awards with performance conditions when it concludes it is probable that the performance conditions will be achieved. The Company reassesses the probability of vesting at each balance sheet date and adjusts compensation costs accordingly.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled, updated as needed for changes in corporate tax rates. The effect on deferred tax assets and liabilities from a change in tax rates is recognized in income in the period that includes the effective date of the change. The Company recognizes tax liabilities or benefits from an uncertain position only if it is more likely than not that the position will be sust ained upon examination by taxing authorities based on the technical merits of the issue. The amount recognized would be the largest liability or benefit that the Company believes has greater than a 50% likelihood of being realized upon settlement.
Income Per Share	Income Per Share Basic income per common share is computed by dividing the net income by the weighted-average number of common shares outstanding during the period, less unvested restricted stock awards. Diluted income per common share is computed by dividing net income by the weighted-average common shares and potentially dilutive common share equivalents using the treasury stock method.
Segment Information and Disaggregated Revenue	Segment Information and Disaggregated Revenue The Company operates in a single operating segment by selling products directly to customers and through an international network of independent consultants that operates in an integrated manner from market to market. Commissions and incentives expenses are the Company’s largest expense comprised of the commissions paid to its independent consultants. The Company manages its business primarily by managing its international network of independent consultants. The Company disaggregates revenue in two geographic regions: the Americas region and the Asia/Pacific & Europe region.
New Accounting Pronouncements	New Accounting Pronouncements In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"), expanding segment disclosure requirements. The amendments require enhanced disclosure for certain segment items and required disclosure on how management uses reported measures to assess segment performance. The amendments do not change how segments are determined, aggregated, or how thresholds are applied to determine reportable segments. ASU 2023-07 is effective for the Company’s annual periods beginning July 1, 2024, and for interim periods beginning July 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"). The guidance requires disclosure of disaggregated income taxes paid, prescribes standardized categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU 2023-09 is effective for the Company’s annual periods beginning July 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures. In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses ("ASU 2024-03"). The guidance requires disclosure, in the notes to financial statements, of specific information about certain costs and expenses at each interim and annual reporting period. ASU 2024-03 is effective for the Company’s annual periods beginning July 1, 2027, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures. Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company's present or future financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Schedule of Components of Inventory	As of December 31, 2024 and June 30, 2024, inventory consisted of (in thousands): December 31, June 30, Finished goods $ 13,900 79.6 % $ 11,841 78.7 % Raw materials 3,567 20.4 % 3,214 21.3 % Total inventory $ 17,467 100.0 % $ 15,055 100.0 %
Schedule of Computation of Net (Loss) Income Per Share	The following is a reconciliation of net income per share and the weighted-average common shares outstanding for purposes of computing basic and diluted net income per share (in thousands, except per share amounts): Three Months Ended December 31, Six Months Ended December 31, 2024 2023 2024 2023 Numerator: Net income (loss) $ 2,550 $ (656) $ 4,376 $ (27) Denominator: Basic weighted-average common shares outstanding 12,211 12,612 12,166 12,574 Effect of dilutive securities: Stock awards and options 966 — 737 — Diluted weighted-average common shares outstanding 13,177 12,612 12,903 12,574 Net income (loss) per share, basic $ 0.21 $ (0.05) $ 0.36 $ 0.00 Net income (loss) per share, diluted $ 0.19 $ (0.05) $ 0.34 $ 0.00
Schedule of Revenue Disaggregated by Geographic Regions	The following table presents the Company's revenue disaggregated by these two geographic regions (in thousands): Three Months Ended December 31, Six Months Ended December 31, 2024 2023 2024 2023 Americas $ 57,154 $ 39,065 $ 94,046 $ 77,580 Asia/Pacific & Europe 10,608 12,559 20,930 25,408 Total revenue $ 67,762 $ 51,624 $ 114,976 $ 102,988 Additional information as to the Company’s revenue from operations in the most significant geographical areas is set forth below (in thousands): Three Months Ended December 31, Six Months Ended December 31, 2024 2023 2024 2023 United States $ 55,381 $ 37,219 $ 90,649 $ 74,115 Japan $ 6,278 $ 7,314 $ 12,261 $ 14,828
Schedule of Long-lived Assets by Geographic Areas	The following table presents the Company's long-lived assets for its most significant geographic markets (in thousands): December 31, June 30, United States $ 19,582 $ 19,216 Japan $ 1,879 $ 1,925

Leases (Tables)

Leases (Tables)	6 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Schedule of Lease, Cost	The components of lease expense for the three and six months ended December 31, 2024 and 2023, were as follows: Three Months Ended December 31, Six Months Ended December 31, 2024 2023 2024 2023 Operating lease expense Operating lease cost $ 468 $ 462 $ 938 $ 992 Variable lease cost 33 45 74 94 Short-term lease costs 4 12 9 23 Total lease expense $ 505 $ 519 $ 1,021 $ 1,109 Supplemental cash flow information related to operating leases was as follows (in thousands): Three Months Ended December 31, Six Months Ended December 31, 2024 2023 2024 2023 Operating cash outflows from operating leases $ 564 $ 755 $ 1,129 $ 1,090 Right-of-use assets obtained in exchange for lease obligations $ — $ — $ — $ 1,502
Schedule of Maturity of Lease Liabilities	Maturity of lease liabilities at December 31, 2024 are as follows (in thousands): Year ended June 30, Amount 2025 (remaining six months ending June 30, 2025) $ 1,142 2026 2,314 2027 2,316 2028 2,045 2029 1,772 Thereafter 4,622 Total 14,211 Less: imputed interest (1,442) Present value of lease liabilities $ 12,769

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Details) shares in Thousands			3 Months Ended		6 Months Ended
	Dec. 31, 2024 USD ($)	Jun. 30, 2024 USD ($)	Dec. 31, 2024 USD ($) shares	Dec. 31, 2023 USD ($) shares	Dec. 31, 2024 USD ($) segment region shares	Dec. 31, 2023 USD ($) shares
Concentration Risk [Line Items]
Foreign currency transaction gain (loss), realized			$ (500,000)	$ 37,000	$ (500,000)	$ (100,000)
Bad debt expenses			0	0
Inventory valuation reserves	$ 1,000,000	$ 1,300,000	1,000,000		1,000,000
Deferred revenue	$ 1,400,000	900,000	1,400,000		1,400,000
Revenue recognized related to accrued loyalty points			$ (300,000)	100,000	$ (500,000)	(40,000)
Money back guarantee period					30 days
Return period for resalable and restockable Items					12 months
Refund percent for resalable and restockable Items	100%		100%		100%
Handling and restocking fee, percentage (as a percent)	10%		10%		10%
Return liability reserve	$ 200,000	100,000	$ 200,000		$ 200,000
Research and development			200,000	100,000	500,000	300,000
Income tax expense			$ 539,000	$ (456,000)	$ 1,291,000	$ (256,000)
Antidilutive securities excluded from EPS calculation (in shares) | shares			100	26	100	100
Number of geographic segments | region					2
Number of operating segments | segment					1
Cash accounts held primarily at One Financial Institution
Concentration Risk [Line Items]
Concentration of credit risk	18,000,000	12,600,000
Cash held primarily at Other Financial Institutions
Concentration Risk [Line Items]
Concentration of credit risk	$ 3,600,000	$ 4,300,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Components of Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Jun. 30, 2024
Inventory Disclosure [Abstract]
Finished goods	$ 13,900	$ 11,841
Raw materials	3,567	3,214
Total inventory	$ 17,467	$ 15,055
Finished goods, percent of inventory (in percentage)	79.60%	78.70%
Raw materials, percent of inventory (in percentage)	20.40%	21.30%
Percent of total inventory (in percentage)	100%	100%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summary of Computation of Net (Loss) Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended				6 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2024	Dec. 31, 2023
Numerator:
Net income (loss)	$ 2,550	$ 1,826	$ (656)	$ 629	$ 4,376	$ (27)
Denominator:
Basic weighted-average common shares outstanding (in shares)	12,211		12,612		12,166	12,574
Effect of dilutive securities:
Stock awards and options (in shares)	966		0		737	0
Diluted weighted-average common shares outstanding (in shares)	13,177		12,612		12,903	12,574
Net income per share, basic (in USD per share)	$ 0.21		$ (0.05)		$ 0.36	$ 0
Net income per share, diluted (in USD per share)	$ 0.19		$ (0.05)		$ 0.34	$ 0

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Jun. 30, 2024
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue, net	$ 67,762	$ 51,624	$ 114,976	$ 102,988
Americas
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue, net	57,154	39,065	94,046	77,580
Asia/Pacific & Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue, net	10,608	12,559	20,930	25,408
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue, net	55,381	37,219	90,649	74,115
Long-lived assets	19,582		19,582		$ 19,216
Japan
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue, net	6,278	$ 7,314	12,261	$ 14,828
Long-lived assets	$ 1,879		$ 1,879		$ 1,925

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Jun. 30, 2024
Lessee, Lease, Description [Line Items]
Weighted average remaining lease term	6 years 5 months 4 days		6 years 5 months 4 days		6 years 10 months 24 days
Weighted average discount rate (as a percent)	3.45%		3.45%		3.46%
Operating lease expense	$ 0.5	$ 0.5	$ 1	$ 1.1
Minimum
Lessee, Lease, Description [Line Items]
Lease term	1 year		1 year
Maximum
Lessee, Lease, Description [Line Items]
Lease term	7 years		7 years

Leases - Schedule of Lease, Cos

Leases - Schedule of Lease, Cost (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Leases [Abstract]
Operating cash outflows from operating leases	$ 564	$ 755	$ 1,129	$ 1,090
Right-of-use assets obtained in exchange for lease obligations	$ 0	$ 0	$ 0	$ 1,502

Leases - Schedule Of Lease Expe

Leases - Schedule Of Lease Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Operating lease expense
Operating lease cost	$ 468	$ 462	$ 938	$ 992
Variable lease cost	33	45	74	94
Short-term lease costs	4	12	9	23
Total lease expense	$ 505	$ 519	$ 1,021	$ 1,109

Leases - Schedule of Maturity o

Leases - Schedule of Maturity of Lease Liabilities (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Leases [Abstract]
2025 (remaining six months ending June 30, 2025)	$ 1,142
2026	2,314
2027	2,316
2028	2,045
2029	1,772
Thereafter	4,622
Total	14,211
Less: imputed interest	(1,442)
Present value of lease liabilities	$ 12,769

Long-Term Debt (Details)

Long-Term Debt (Details) - Revolving Credit Facility - USD ($)	Apr. 12, 2024	Dec. 31, 2024
Line of Credit
Line of Credit Facility [Line Items]
Effective rate		6.49%
March 2016 Revolving Loan
Line of Credit Facility [Line Items]
Floor interest rate (as a percent)	0%
Basis spread on variable rate (as a percent)	2%
March 2016 Revolving Loan | Line of Credit
Line of Credit Facility [Line Items]
Maximum capacity on draw	$ 5,000,000

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Aug. 30, 2023	Feb. 17, 2022	Feb. 16, 2022
Class of Stock [Line Items]
Shares issued for stock option exercises (in shares)	0	0
Repurchase common stock amount authorized (up to)						$ 60,000,000	$ 35,000,000
Stock repurchase program shares repurchased (in shares)	0	300,000	100,000	400,000
Repurchase of company stock	$ 0	$ 1,900,000	$ 1,114,000	$ 2,671,000
Remaining authorized repurchase amount	$ 19,300,000		19,300,000
Number of rights					1
Exercise price of rights (in dollars per share)					$ 20
Percent of common stock acquisition that makes rights exercisable					12%
Percent of common stock acquisition that makes rights exercisable, passive investors					20%
Discount percent					50%
Cash dividend paid (in dollars per share)	$ 0.04	$ 0.035		$ 0.47
Dividends, common stock, cash	$ 500,000	$ 500,000	$ 1,000,000	$ 6,000,000
Cash dividend, common stock declared (in dollars per share)	$ 0.04
Common Stock
Class of Stock [Line Items]
Shares issued under equity award plan (in shares)	100,000	500,000	300,000	800,000
Shares canceled or surrendered as payment of tax withholding (in shares)	100,000	34,000	100,000	100,000

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($)		1 Months Ended					3 Months Ended		6 Months Ended
	Feb. 16, 2017	Nov. 30, 2023	Nov. 30, 2022	Nov. 30, 2020	Nov. 30, 2018	Feb. 28, 2018	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Aug. 31, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issued under employee stock purchase plan (in shares)									22,000	39,000
Compensation							$ 1,700,000	$ 800,000	$ 2,600,000	$ 1,700,000
2017 Long-Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional shares authorized (in shares)	650,000	1,138,000	1,052,000	650,000	715,000	425,000
Number of shares authorized (in shares)							5,100,000		5,100,000
Right to purchase common stock, non-vested and outstanding, exercise price (in USD per share)							$ 4.44		$ 4.44
Share based payment award, vesting period									3 years
Options outstanding, net of awards expired (in shares)							100,000		100,000
2017 Long-Term Incentive Plan Excluding 2010 Long-Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)							4,630,000		4,630,000
2010 Long-Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)							475,000		475,000
Contractual term of stock options granted									10 years
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, capital shares reserved for future issuance (in shares)							800,000		800,000		400,000
Shares available for issuance under the ESPP (in shares)							400,000		400,000
Purchase price of common stock (as a percent)									85%
Maximum employee subscription rate (as a percent)							15%		15%
Maximum number of shares per employee (in shares)									3,000
Amount in excess of fair market value of stock for option not to be granted							$ 25,000		$ 25,000
Offering period									6 months